Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | METAP1 | P53582 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2419303 | 0.89 | LMNA (0.48) | LMNAGAAKDM4EALDH1A1SIGMAR1 | |
| SCHEMBL5679577 | 0.85 | LMNA (0.47) | LMNAGAAKDM4EALDH1A1SIGMAR1 | |
| SCHEMBL15724892 | 0.85 | LMNA (0.50) | LMNAGAAKDM4EALDH1A1SIGMAR1 | |
| SCHEMBL503654 | 0.84 | SIGMAR1 (0.57) | LMNAGAAKDM4EALDH1A1SIGMAR1 | |
| SCHEMBL1207853 | 0.83 | SIGMAR1 (0.56) | LMNAGAAKDM4EALDH1A1SIGMAR1 | |
| SCHEMBL6461145 | 0.83 | SIGMAR1 (0.53) | LMNAGAAKDM4EALDH1A1SIGMAR1 | |
| SCHEMBL13485788 | 0.81 | PDE5A (0.67) | LMNAGAAKDM4EALDH1A1SIGMAR1 | |
| SCHEMBL5266396 | 0.80 | KDM4E (0.56) | LMNAGAAKDM4EALDH1A1CYP19A1 | |
| SCHEMBL22319275 | 0.79 | GAA (0.52) | LMNAGAAKDM4EALDH1A1CYP19A1 | |
| SCHEMBL22319274 | 0.79 | GAA (0.52) | LMNAGAAKDM4EALDH1A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922832-B1 | GLUTAMINASE INHIBITORS AND METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-9303002-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-22 | — | — | US | disclosed |
| US-20140142146-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-05-22 | — | — | US | disclosed |
| US-8106048-B2 | protozoal infestations in humans and animals, by bacteria, viruses or proteinaceous agents; neurological diseases or disorders; ischemia and/or reperfusion injury; 4-(4-Ethoxycarbonyl-4,5-dihydro-thiazol-2-yl)-piperidine-1-carboxylic acid t-butyl ester | 4SC AG (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-10-21 | — | — | US | disclosed |
| US-7812041-B2 | Heterocyclic NF-κB inhibitors | 4SC AG (DE) | 2010-10-12 | — | — | US | disclosed |
| US-20100048574-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20100004258-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-01-07 | — | — | US | disclosed |
| US-7601745-B2 | Heterocyclic NF-kB inhibitors | 4SC AG (DE) | 2009-10-13 | — | — | US | disclosed |
| US-20080261971-A1 | Novel Heterocyclic Nf-Kb Inhibitors | 4SC AG (DE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKB2, NFKBIA, NFRKB | LMNA 2529/4885GAA 4792/4885KDM4E 1244/4885 |
| US-20100048574-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | NFKBIA, IKBKB, NFKB2 | LMNA 1371/4885GAA 1190/4885KDM4E 1503/4885 |
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | GLS, GLS2, GLUL | LMNA 4026/4885GAA 24/4885KDM4E 959/4885 |
| US-20080261971-A1 | Novel Heterocyclic Nf-Kb Inhibitors | NFKBIA, NFKB2, NFRKB | LMNA 4447/4885GAA 4160/4885KDM4E 2640/4885 |
| US-20140142146-A1 | COMPOUNDS AND THEIR METHODS OF USE | GLS, GLS2, GLUL | LMNA 3478/4885GAA 19/4885KDM4E 800/4885 |
| US-20100004258-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKBIA, IKBKB, NFKB2 | LMNA 1220/4885GAA 1096/4885KDM4E 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.